Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. Livdelzi … Read more
Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on … Read more
It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply addressing the symptoms. It was this type of breakthrough that Robert … Read more
The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments … Read more
The narrative that’s been peddled for the past three decades has seen obesity become mired in controversy, leading many – even healthcare professionals – to view it as a lifestyle choice rather than a disease. Nearly 40% of the global population has a body mass index (BMI) higher than 25 kg/m2, meaning they’re overweight or … Read more
Paul Evans, Velocity President and CEO, was featured in a Triangle Business Journal article covering Velocity’s recent partnership announcement with Luminis Health. As Paul notes in the article, hospitals play a crucial role in clinical research due to their patient populations, particularly in specialized fields like oncology. Velocity will take over the operation of the hospital’s … Read more
Kris Kowdley, MD, contributed significantly to the clinical research program that led to accelerated FDA approval of Ipsen’s Iqirvo, a first-in-class treatment for primary biliary cholangitis (PBC), a rare liver disease. As a primary investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s site enrolled the first patient in the study, and he was the … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, and Luminis Health, a nonprofit health system providing care for 1.8 million people, today announce their partnership to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs. The partnership will involve Velocity taking over operation of the hospital’s existing clinical … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting health equity in clinical trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trial science and deliver vital new … Read more
It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA, Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council, discusses their importance to patients yesterday, today, and tomorrow. Dr. Cromwell is board-certified in Family Medicine and Clinical Lipidology with over 20 years of clinical research experience. As he … Read more